Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy
NCT ID: NCT00655330
Last Updated: 2016-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
170 participants
INTERVENTIONAL
2008-05-31
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus
NCT00419835
CSPPT- Chronic Kidney Diseases Study
NCT01871740
The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value
NCT04572724
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
NCT00775840
Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome
NCT05053893
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day)
* Arm 2: Valsartan + Placebo Valsartan (160mg/day) + Placebo
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Valsartan (160mg/day)is given in combination with Placebo
Valsartan
Valsartan (160mg/day)
Placebo
Placebo
2
Valsartan (160mg/day) + Probucol (750mg/day)
Valsartan
Valsartan (160mg/day)
Probucol
Probucol (750mg/day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Valsartan
Valsartan (160mg/day)
Placebo
Placebo
Probucol
Probucol (750mg/day)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Urinary albumin excretion 1-3g/24hours
* Serum creatinine \< 3mg/dl
Exclusion Criteria
* Renal diseases other than type 2 Diabetes nephropathy
* Renal artery stenosis
* Severe heart diseases
* Tuberculosis
30 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Guangdong Provincial People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Shi
Director of renal division of Guangdong General Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shi Wei, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Nephrology Dept.,Guangdong General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guangdong General Hospital
Guangzhou, Guangdong, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GPPH200603 -1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.